News Search Results
Nov 17, 2025, 07:00 ET BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.
Nov 13, 2025, 07:00 ET Tract Bio Announces Opening of New Laboratory at The Pearl Innovation District
platform, stemECHO™, to transform treatment of highly-prevalent cancers and inflammatory diseases, including chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML), oesophageal adenocarcinoma, lung, pancreatic, ovarian and gastric cancer, as well as chronic obstructive pulmonary
More news about: Tract Bio
Nov 12, 2025, 09:30 ET Pillar Biosciences Enables Rapid, Localized Tumor Profiling of Lymphoid Malignancies with Launch of New Kitted NGS Panel
diagnosed with leukemia, lymphoma, or myeloma. An estimated combined total of 187,740 people in the U.S. were expected to be diagnosed with leukemia, lymphoma or myeloma in 2024. New cases of leukemia, lymphoma, and myeloma were expected to account for 9.4
More news about: Pillar Biosciences, Inc.
Nov 12, 2025, 07:00 ET Paula and Rodger Riney Foundation Pledges $1.5 Million Matching Grant to Support HealthTree Foundation's End-of-Year Appeal for Blood Cancer Research
The Paula and Rodger Riney Foundation, established by Paula and Rodger Riney following Rodger's own diagnosis with multiple myeloma, has become a leading funder of myeloma research across major institutions worldwide, with more than $80 million invested to date. This new partnership underscores the
More news about: HealthTree Foundation
Nov 10, 2025, 01:22 ET Jiahui International Cancer Center Attracts Global Patients with Advanced CAR-T Therapy
/PRNewswire/ -- On November 7, Jiahui International Cancer Center (JICC) successfully treated a 78-year-old patient from New Zealand with relapsed multiple myeloma using CAR-T therapy, highlighting JICC's growing reputation as a destination for cutting-edge oncology care for international patients. The patient
More news about: Jiahui Health
Nov 07, 2025, 08:30 ET FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
multiple myeloma," said Dr. Helen Torley, President and CEO of Halozyme. "The approval expands the indications for DARZALEX Faspro with ENHANZE, further solidifying its role as a cornerstone therapy across all stages of multiple myeloma." Smoldering multiple myeloma (SMM) is
More news about: Halozyme Therapeutics, Inc.
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
FASPRO® reducing the risk of disease progression to active multiple myeloma or death by 51 percent compared to active monitoring, according to the International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma. Today's milestone follows the
More news about: Johnson & Johnson
Nov 06, 2025, 07:00 ET SkylineDx Wins 2025 BioTech Breakthrough Award for "Diagnostics Company of the Year"
Breakthrough Awards program for its portfolio of genomic assay tests, including the Merlin CP-GEP Test for cutaneous melanoma and SKY92 test for multiple myeloma. "At SkylineDx, we're not just developing diagnostics – we're changing how patients and doctors navigate critical treatment
More news about: SkylineDx
Nov 05, 2025, 10:02 ET Black Health Matters Brings Star Power and Life-Saving Screenings to Charlotte on November 15th
Free health screenings: valued at over $1,000, including Lung Cancer Risk Assessment/Referrals for Screening, Multiple Myeloma Risk Assessment, Iron Screening, PSA Screening, Blood Pressure Screening, and more. Complimentary
More news about: Black Health Matters
Nov 05, 2025, 08:30 ET Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting
UCCT-BCMA-1: A First-in-Human, Non-Viral CRISPR-Engineered CAR T Cell Therapy Targeting BCMA in Relapsed/Refractory Multiple Myeloma (Top 150
More news about: Parker Institute for Cancer Immunotherapy
Nov 04, 2025, 06:20 ET Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
of bispecific antibodies in advanced-stage myeloma management. In parallel, advances in genetic risk stratification and molecular profiling are redefining how patients are categorized and treated. Emerging models for MGUS, smoldering myeloma, and active disease now incorporate genomic and
More news about: DataM Intelligence 4 Market Research LLP
Nov 03, 2025, 22:23 ET 【2025 ASH】 亞盛醫藥Bcl-2抑制劑利沙托克拉兩項臨床研究入選，含1項口頭報告！
immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) 胚胎外胚層發育（EED）抑制劑APG-5918單藥在多發性骨髓瘤（MM）臨床前模型中克服了免疫調節藥物（IMiD）耐藥性並顯示了與IMiDs/Cereblon
More news about: 亞盛醫藥
Nov 03, 2025, 20:58 ET 口頭報告！維立志博5項血液腫瘤領域研究成果重磅登陸2025 ASH年會
of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma摘要號：91報告類型：口頭報告報告時間：美國東部時間2025.12.06 9:30 AM – 9:45 AM（大會首日首場口頭報告專場第一個彙報）報告地點：OCCC - West Hall D2本研究（N
More news about: 維立志博
Nov 03, 2025, 20:22 ET 【2025 ASH】亞盛醫藥耐立克®多項研究入選，POLARIS-1研究數據首次發布
IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) 胚胎外胚層發育（EED）抑制劑APG-5918單藥在多發性骨髓瘤（MM）臨床前模型中克服了免疫調節藥物（IMiD）耐藥性並顯示了
More news about: 亞盛醫藥
Nov 03, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Nov 03, 2025, 16:01 ET HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
a new indication for DARZALEX® SC as a monotherapy for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma. Third Quarter 2025 Financial Highlights:
More news about: Halozyme Therapeutics, Inc.
Nov 03, 2025, 09:41 ET Canopy and Willamette Valley Cancer Institute and Research Center Announce Partnership to Improve Care Between Visits
Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting6Canopy internal
More news about: Canopy
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ platform for relapsed/refractory multiple myeloma (R/R MM), and for CT1190B, an allogeneic CD19/CD20-targeting CAR-T product candidate for relapsed/refractory non-Hodgkin's lymphoma (R/R NHL). The
More news about: CARsgen Therapeutics
Nov 03, 2025, 09:01 ET Orna Therapeutics Announces Multiple Presentations Supporting its in vivo CAR Programs for Autoimmune Diseases at the 67th American Society of Hematology Annual Meeting
Title: In Vivo pan CAR Therapy Utilizing Circular RNA for Treatment of Multiple MyelomaSpeaker: Rebecca Silver, Ph.D., Pr. Scientist, Orna TherapeuticsDate/Time: Sunday, December 7, 2025, 6:00 PM – 8:00
More news about: Orna Therapeutics
Nov 03, 2025, 09:00 ET STAND UP TO CANCER FUNDS TEAM OF RESEARCHERS TO EXPLORE NEW APPROACHES THAT ADVANCE AL AMYLOIDOSIS TREATMENT
treating immunoglobulin light chain (AL) amyloidosis. AL amyloidosis is a rare and challenging disease linked to blood cancers, particularly multiple myeloma, as well as lymphomas or chronic lymphocytic leukemia. This funding is made possible through the collaboration announced last year with Johnson &
More news about: Stand Up To Cancer
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
(n=117). The trial is being conducted in collaboration with the European Myeloma Network and is evaluating the all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 in their immediate prior line of therapy.
More news about: Karyopharm Therapeutics Inc.
Oct 31, 2025, 13:51 ET Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy
as winners in May for pioneering CAR T-cell therapy, a technology that has reshaped how physicians treat leukemia, lymphoma, and multiple myeloma — and is now showing promise in treating autoimmune and infectious diseases [
More news about: Broad Institute
Oct 30, 2025, 17:30 ET Revenue Cycle Management (RCM) Market to Grow at 45.95% CAGR, Surpassing USD 28560 Billion by 2035 | Vantage Market Research
Browse More Related Reports: Multiple Myeloma Market is valued at USD 28.42 Billion in 2024 and is projected to reach a value of USD 59.015 Billion by 2035 at a CAGR (Compound Annual Growth Rate)
More news about: Vantage Market Research
Oct 30, 2025, 03:28 ET U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
data confirming the therapeutic equivalence to XGEVA. In the U.S., OSENVELT is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable
More news about: Celltrion
Oct 29, 2025, 15:25 ET Eminent Physician-Scientist Dr. Jonathan D. Licht to Serve as Next President and Chief Scientific Officer of Van Andel Institute
lymphoma and myeloma, with the goal of developing treatments to reverse these processes. His many contributions include identifying mutations that contribute to 10%–20% of relapsed B cell acute lymphocytic leukemia (ALL) cases in children. These mutations also are present in 15%–20% of multiple myeloma cases
More news about: Van Andel Institute